Search Results for "300 Years Of Andrew Witty"
Original Source: 300 years of Andrew Witty? What to buy with $3 billion
GlaxoSmithKline, part of what used to be called 'the ethical pharmaceutical industry' back in the days when Boy Scouts wore short pants, was docked a record $3 billion in state and federal fines and in liabilities in the US for.....
Matching Channels
Generics Drugs - news, views, reports
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration,...
Lymphoma is a cancer of the lymph nodes; classified as Hodgkin or non-Hodgkin lymphoma. Malignancy varies, and the prognosis can be from a few months to many years. Symptoms include enlarged lymph...
Research has not found any adverse effects from consuming vitamin E in food. However, high doses of alpha-tocopherol supplements can cause hemorrhage and interrupt blood coagulation in animals, and...
Fibroblast Growth Factors FGFs
The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development. Quite a number of FGF-R ag...
Clinical trials involving new drugs are commonly classified into four phases. Each phase of the drug approval process is treated as a separate clinical trial. The drug-development process will norma...
Matching News
GlaxoSmithKline's CEO Sir Andrew Witty has named a couple of compounds that the firm is open to partnering on. Describing during an R&D review for analysts how the company intends to "stay focused...
GSK's Witty looking for partners for albiglutide & retosiban
GlaxoSmithKline's CEO Sir Andrew Witty has named a couple of compounds that the firm is open to partnering on. Describing during an R&D review for analysts how the company intends to "stay focused...
Letter from EFPIA President, Sir Andrew Witty, to European Heads of States and Governments
BRUSSELS, June 25, 2012 - The European Federation of Pharmaceutical Industries and Associations (EFPIA) today posted on its website a letter sent to the European "Heads of States and Governments"...
Witty: 'Others will follow in GSK's transparency footsteps…eventually'
GlaxoSmithKline's CEO Sir Andrew Witty today pledged to boldly go where no pharma has been before: the UK-based big pharma is going to make available the detailed anonymised patient-level data that s...
During a celebration to mark GSK’s 40th year in Singapore, CEO Andrew Witty announces new investments in work-horse manufacturing plants and reaffirms openness to share patient data from clinical st...
The Glaxo CEO & His Public Relations Debacle
Earlier this week, GlaxoSmithKline ceo Andrew Witty made an unusual statement. In response to a $3 billion settlement with the US Department of Justice, which alleged the drugmaker engaged in off-labe...
Witty warns EU leaders over pricing
Sir Andrew Witty has waded into the debate over Europe’s economic future with a plea for pharma innovation to be made into one of the main planks of recovery and growth. In an open letter to EU lead...
GlaxoSmithKline's CEO Discusses Q4 2012 Results - Earnings Call Transcript
GlaxoSmithKline plc (GSK) Q4 2012 Earnings Call February 6, 2013 9:00 am ET Executives Sir Andrew Witty – Chief Executive Officer Simon Dingemans – Chief Financial Officer Analysts An...
Matching PubMed Articles
Copolymer-templated nitrogen-enriched porous nanocarbons for CO(2) capture.
Nitrogen-enriched porous carbon materials made via the carbonization of polyacrylonitrile containing block copolymer act as efficient and highly selective CO(2) sorbents. Nitrogen content and surface...
Evolutionary biology: Oh sibling, who art thou?
Accelerating the pulse of cardiovascular R&D.
Renewed commitment to cardiovascular drug development is needed to combat what is likely to be the leading cause of death for the next two decades. How might this be achieved?
Potent oxidative DNA cleavage by the di-copper cytotoxin: Cu(2)(μ-terephthalate)(1,10-phen)(4)(2+).
The di-copper(ii) cation, [Cu(2)(μ-terephthalate)(1,10-phen)(4)](2+), is a powerful, non-sequence-specific, minor-groove oxidizer of duplex DNA which, unlike copper(ii) bis-1,10-phenanthroline chlori...
